The Venture Codex

Led · Equity · Nov 2025

Semalytix GmbH, based in Bielefeld, Germany, offers an Agentic AI platform that lets pharmaceutical teams compliantly tap into the "global patient voice" and embed those insights directly into drug-development workflows. Powered by PatientGPT, the company’s Atlas platform aggregates 100 million public social data points, 33 million medical publications, and more than 400,000 clinical-trial outcomes to create role-specific AI agents for pharma users. Its "Agent-as-a-Service" approach allows clients to build proprietary AI models and compounding intellectual property rather than relying on one-off research projects. Semalytix has already secured commercial traction with several top-20 pharmaceutical companies. With the majority of pharma workflows estimated to be 75–85 % automatable or augmentable by AI, management believes the addressable market is large and urgent. Proceeds from the latest funding will be used to enhance the platform’s capabilities, grow the AI, customer-success, and commercial teams, and expand internationally, particularly across Europe and the United States.

Led · Series A · Sep 2025

Actuals develops a SaaS platform that serves as a smart link between order, payment and accounting systems, automatically matching, reconciling and journaling millions of daily transactions. The software flags discrepancies in real time, produces complete audit trails and accelerates month-end closings, reducing revenue leakage and manual workload for finance departments. Founded by Peter Engel, Stefan de Kraker and Peter Lem and headquartered in Amsterdam, the company targets e-commerce, mobility and marketplace businesses that face high transaction volumes and increasing regulatory scrutiny. Actuals’ technology is already trusted by leading e-commerce platforms and marketplaces in Europe and North America, confirming its product–market fit. With the newly raised capital the team plans to deepen automation, improve user experience and build tighter integrations, while executing a blueprint for international expansion. Although specific revenue figures were not disclosed, the company positions itself as critical financial infrastructure for modern digital companies and aims to scale rapidly on the back of growing transaction complexity.

Participated · Equity · Feb 2025

Sirius Medical develops the Sirius Pintuition surgical navigation platform and GPSDetect software to enable wire‑free localization for breast‑conserving surgery. The Pintuition system is CE marked and FDA cleared and has been praised by breast cancer surgeons. The company traces its roots to the Netherlands Cancer Institute and reports adoption in over 250 centers and 35,000 procedures globally. Sirius Medical is focused on improving usability and extending applications of its platform. The company announced it secured €10M in additional scale‑up funding to support product development and global expansion. The investment will also be used to bolster sales infrastructure and enter new markets. Sirius Medical develops Pintuition, a surgical marker navigation system that gives surgeons real-time distance and directional guidance to locate tumors. The company is led by CEO Bram Schermers and is focused on improving care for cancer patients by enabling precise and efficient tumor removal. Pintuition is active in over 100 centers with more than 5,000 procedures across Western Europe and the US. Sirius experienced revenue growth in 2022 and has built an international sales network in Europe and the USA. The company plans to use new funding to accelerate worldwide growth of Pintuition, support further product development, and expand commercial roll-out. Sirius Medical has commercially launched the Sirius Pintuition System, a localisation platform designed to help surgeons pinpoint breast tumours during surgery. The system is CE marked and Sirius is pursuing FDA clearance. The Pintuition seed can be placed up to 180 days before surgery and the intraoperative probe gives real-time feedback and directional guidance to marked tissue. Sirius positions Pintuition as an easy-to-use, affordable alternative to metal anchor wires and radioactive seeds, aiming to improve hospital workflow and surgical accuracy. The company is developing a pipeline of complementary products and indications alongside the commercial rollout. Management says recent funding will be used to execute growth plans and advance the product pipeline.

Led · Equity · Aug 2024

Uman offers an AI-driven software platform designed to increase the effectiveness and efficiency of B2B sales teams by leveraging smart data governance and generative AI. The platform assists sales professionals with meeting preparation, creating sales materials, and personalizing sales pitches. Uman’s AI agent is already in use at customers in IT, consultancy, and telecoms, including Proximus, msg global, and DPG Media. The company was founded by Charles Bouten and Sven Degroote and is headquartered in Ghent, Belgium. Uman plans to use the new capital to expand its international presence, particularly across Western Europe. The company reported a €1.9M funding raise in August 2024.

Led · Equity · Aug 2024

Uman is a Ghent-based AI-driven software platform for B2B sales teams that built the sales AI agent, uman. The product uses smart data governance and generative AI to surface sales content and actionable insights at the right times, enabling personalized pitches and offers without manual research. Uman positions this workflow to increase conversion rates, efficiency and cross-sell opportunities. Several Western European customers already use the agent, including Proximus, msg global and DPG Media, and the company reports customers in the Netherlands and Germany. The founders, Charles Boutens (CEO) and Sven Degroote (CTO), say the company will focus on Europe while aiming to expand to the US. The company has raised €1.9 million in the described funding round to support scaling, team growth and product development. uman.ai builds a workforce knowledge base that maps the skills and interests of employees using deep-learning algorithms. The platform gives management an overview of team knowledge and aims to help employees gain greater insight into their competencies. The company positions the product as a way to reduce turnover caused by poor task-skill and interest matches. uman.ai has raised €500,000 to develop a go-to-market strategy and also received innovation grants from VLAIO. Investors named in the round include imec.istart, Skyhaus, and Roel Naessens. The startup was founded one year ago and is part of imec.istart’s acceleration program; founder Charles Boutens conceived the idea while working at ML6, whose parent company Skyhaus is an investor.